AbbVie Reports Third-Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
AbbVie (ABBV) Tops Q3 EPS by 8c, Beats on Revenue; Offers FY25 EPS Guidance
October 31, 2025 7:50 AM EDTAbbVie (NYSE: ABBV) reported Q3 EPS of $1.86, $0.08 better than the analyst estimate of $1.78. Revenue for the quarter came in at $15.78 billion versus the consensus estimate of $15.58 billion.
GUIDANCE:
AbbVie sees FY2025 EPS of $10.61-$0.65, versus the consensus of $10.86.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More